Short term n=9 (disease ≤2 years) | Long term n=8 (disease ≥10 years) | p Value | |
---|---|---|---|
Age | 34.22±9.72 | 41.23±8.04 | 0.134 |
Gender: % female | 100 | 100 | na |
Ethnicity | ns | ||
African American | 22% | 63% | |
Hispanic | 44% | 37% | |
Caucasian | 22% | 0% | |
Asian | 12% | 0% | |
Education (years) | 14.67±2.4 | 12.29±6.05 | 0.296 |
SLEDAI | 2.22±2.05 | 3.25±3.2 | 0.437 |
Damage index | 0.33±0.5 | 1.25±0.71 | 0.007* |
STAI | 36.44±11.77 | 35±7.96 | 0.774 |
BDI | 10.78±11.16 | 6.88±3.72 | 0.346 |
Prednisone | 2.64±3.45 | 2.06±2.86 | 0.715 |
Anti-dsDNA titre* | 1.03±0.66 | 1.12±0.92 | 0.819 |
DNRAb titre | 0.30±0.15 | 0.29±0.09 | 0.774 |
Frequency DNRAb+ | 66.7% | 54.5% | 0.858 |
Frequency anti-Ro+ | 33.3% | 50% | 0.486 |
C3 | 107.56±25 | 117.13±19.9 | 0.4 |
C4 | 20.89±6.11 | 24.5±13.24 | 0.47 |
Hydroxychloroquine | 55.6% | 87.5% | 0.183 |
Current disease-modifying antirheumatic drug use | 55.6% | 62.5% | 1.0 |
Methotrexate | 22.2% | 0 | 0.265 |
Cellcept | 11.1% | 50% | 0.131 |
Azathioprine | 22.2% | 12.5% | 1.0 |
Cyclophosphamide | 0 | 0 | na |
Hypertension† | 11% | 38% | 0.294 |
Diabetes mellitus† | 0 | 0 | na |
Smoking (ever) | 22.2% | 25% | 0.665 |
All data are reported as frequency (%) or as mean±SD. All data for medications (prednisone, hydroxychloroquine and immunosuppressive medications) refer to current use at the time of evaluation.
*Mean anti-dsDNA titre by ELISA in Diamond lab using same sera as the DNRAb titre.
†Current hypertension or diabetes mellitus requiring medication.
BDI, Beck Depression Index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; STAI, State Trait Anxiety Inventory.